{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-326995","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-07-31T12:30:33+00:00","discovered_at":"2026-07-31T12:35:00.473160+00:00","generated_at":"2026-07-31T12:35:06.907490+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Karyopharm: Phase 3 endometrial cancer trial misses primary endpoint; plans sNDA for myelofibrosis; exploring financing","bullets":["Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer did not meet primary endpoint of PFS; median PFS 12.75 vs 7.43 months (HR=0.76, p=0.0791).","Company plans to submit sNDA to FDA in August 2026 seeking accelerated approval of selinexor+ruxolitinib for myelofibrosis based on SVR35 at week 24.","FDA requested further discussion on data to support sNDA and conversion to traditional approval; company will provide additional data before submission.","Company, with Centerview Partners, is exploring financing transactions and strategic alternatives to extend cash runway; no assurance of any transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-326995","json":"https://secwatch.observer/filing/0001193125-26-326995.json","markdown":"https://secwatch.observer/filing/0001193125-26-326995.md","text":"https://secwatch.observer/filing/0001193125-26-326995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526326995/0001193125-26-326995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526326995/d71318d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T12:35:06.907490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}